Valinor Discovery

Valinor is a machine learning company focused on accelerating clinical drug development through the construction of multi-modal virtual patient models. The company's core premise is that clinical trials represent the single largest bottleneck in pharmaceutical R&D — accounting for approximately 70% of costs while carrying a roughly 90% failure rate — and that predictive simulation of therapeutic outcomes before human trials begin can address this problem.

Rather than modelling isolated cell behaviour, Valinor builds virtual patient profiles grounded in longitudinal, multi-modal data collected across a broad range of omics and clinical assay types. The approach is designed to simulate how therapies will perform at the level of the whole patient, not individual cells or single experiments.

Data Modalities Incorporated

• Single-cell RNA sequencing from PBMCs and tumour samples
• Single-cell ATAC sequencing from PBMCs and tumour samples
• Whole genome sequencing
• Blood plasma proteomics
• Spatial omics
• Radiology imaging
• Histopathology
• Cell viability assays and cell imaging data
• Circulating tumour DNA (ctDNA)
• Structured clinical data and treatment history

Core Approach and Capabilities

• Generates virtual patient profiles that integrate multi-omics and clinical assay data collected longitudinally, rather than from isolated experiments
• Simulates therapeutic efficacy at the whole-patient level, distinguishing the approach from cell-level or siloed modelling methods
• Uses automated patient simulations trained on large-scale clinical longitudinal datasets to predict how therapies will perform prior to human trials
• Aims to reduce the complexity and failure rates associated with clinical drug development by providing pre-trial predictive clarity

Research and Collaboration

• The company states that its work is supported by a research team and external collaborations, combining academic or scientific research with machine learning development
• Team and collaboration details visible on the website appear to be placeholder content at the time of scraping, so specific personnel and partner names are not available

Valinor's stated goal is to reverse the historically low success rate of clinical trials by providing pharmaceutical developers with simulation tools grounded in the most comprehensive longitudinal clinical datasets assembled for this purpose.